# Efficacy of sacubitril-valsartan combined with rosuvastatin calcium in the treatment of unstable angina pectoris and its effects on blood lipids and hemorheology

## TL;DR

Combining sacubitril-valsartan with rosuvastatin calcium improves outcomes in unstable angina patients without increasing side effects.

## Contribution

Demonstrates the added clinical benefits of combining two drugs for treating unstable angina.

## Key findings

- The combination group showed greater improvement in blood lipid levels compared to the control group.
- Hemorheological and cardiac function indicators improved more significantly in the combination group.
- No significant difference in adverse reactions between the two groups.

## Abstract

To investigate the clinical efficacy of sacubitril-valsartan (SV) combined with rosuvastatin calcium (RC) in the treatment of patients with unstable angina pectoris (UAP).

This was retrospective study. Eighty patients with UAP admitted to The First Affiliated Hospital of Yangtze University from December 2022 to December 2023 were included and divided into observation group (n=40) and control group (n=40) according to treatment regimens. Patients in the control group received RC, while the observation group received SV combined with RC. Clinical efficacy, adverse reactions, and blood lipid, hemorheology, and cardiac function before and six months after treatment were compared between the two groups.

The total efficacy of the observation group was higher than the control group (P<0.05). After six months of treatment, the levels of TG, TC, and LDL-C decreased in both groups, with the observation group showing more significant decrease, while the HDL-C level increased, with the observation group showing more significant increase (P<0.05); The hemorheological indicators of both groups decreased compared to before treatment, and the degree of decrease was more significant in the observation group (P<0.05); Both groups showed significant improvement in cardiac function levels compared to before treatment, with the observation group showing more pronounced improvement (P<0.05). The incidence of adverse reactions in both were not statistically significant different (P=0.712).

The use of SV combined with RC in treatment of UPA has significant clinical effects, improving patients’ blood lipids, hemorheology, and cardiac function indicators without increasing adverse reactions.